|
 Hampton will take the helm at Britain's top pharmaceuticals group at
a testing time. GSK was hit last week by a record $489 million fine
in China for bribing doctors and has warned on profits in 2014 due
to weak sales of its core respiratory drugs.
He will join the board in January, become deputy chairman on April 1
and chairman with effect from Sept. 1, 2015 - or earlier if released
from other commitments.
The long handover reflects the difficulty of replacing Hampton at
RBS ahead of next May's UK general election, given the fact the bank
is 80-percent state-owned and the government will take a keen
interest in the appointment.
Reuters reported on Monday that GSK was under pressure to make
changes, including a possible early replacement of the current
chairman, Chris Gent, as a result of its problems which have
undermined investor confidence.
A person close to the process had previously said that Hampton was
set to be named as GSK's chairman this week.
Several investors see the board change at GSK as overdue -- Gent has
been in the job for nine years -- and analysts at Goldman Sachs
believe a new chairman could "kick-start" change.
Gent, best-known for leading mobile phone company Vodafone during a
period of rapid growth, was due to retire by the end of 2015 and the
drugmaker said it had been planning for his succession over the last
two years.
Before RBS, Hampton chaired supermarket chain Sainsbury and was
group finance director at Lloyds TSB, BT Group, BG Group, British
Gas and British Steel.
GSK will be hoping that the move placates investors while giving its
pressured Chief Executive Andrew Witty time to turn around the
business.
Witty, a veteran GSK insider who was appointed CEO by Gent in 2008,
has been viewed as a star manager for much of his six-year tenure.
But he has been tarnished by the China scandal, which forced GSK to
make an abject apology to the Chinese people last week.
As the new chairman a key task for Hampton will be to help steer the
drugmaker back to sustainable growth and, in the longer term,
potentially finding an eventual successor to Witty.
GSK's share price performance has lagged badly in recent months.
While the Stoxx Europe 600 healthcare sector index has risen by
around a fifth this year on optimism over new drugs, GSK's shares
have lost 11 percent as forecasts for its sales and earnings have
fallen.
The company unveiled a far-reaching asset swap deal with Novartis in
April that will build up its strengths in vaccines and consumer
health, in exchange for exiting the hot area of cancer medicine.
[to top of second column] |
But many analysts believe that even after the Novartis deal closes
next year the new-look GSK will still struggle to grow as rapidly as
its peers.
Possible actions to improve matters could include further
cost-cutting and allocating more capital to buying in promising new
drugs, Goldman analysts said, with a long-term option being to sell
off the vaccines or consumer health operations.
PARACHUTED IN
Hampton has been chairman of RBS since 2009 when he was parachuted
in to help rescue the bank following its 45 billion pounds ($74
billion) bailout during the financial crisis.
He has previously said that a chairman should typically serve
between five and seven years at a listed company and is expected to
stay at RBS until a successor is appointed, according to industry
sources.
Hampton has led RBS through a turbulent period of transition during
which it shed assets worth 1 trillion pounds to rid itself of toxic
loans built up during a period of aggressive lending in the run-up
to the financial crisis.
However, the bank's attempts to return to health have been held back
by the legacy of past misconduct, which included fines of $612
million for the fixing of benchmark interest rates and accusations
over how it treated struggling small firms.
Hampton had hoped to oversee the start of RBS's return to full
private ownership but that prospect is still seen to be several
years away with its shares trading well below the price the
government bought them at, leaving taxpayers sitting on a loss of 13
billion pounds.
(Additional reporting by Matt Scuffham; Editing by Pravin Char and
Greg Mahlich)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
